IE00B4Q5ZN47
© PR Newswire
05.12.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
News Preview
New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomesEight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the epilepsy community and advancing the comprehensive treatment for r...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
News Preview
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancersJazz to host investor webcast on Friday, January 9, 2026, to review dataFor U.S. media and investors onlyDUBLIN, Dec. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced two abstracts...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
News Preview
DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m. PST / 9:45 a.m. EST / 2:45 p.m. GMT....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
18.11.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
News Preview
DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m. PST / 9:45 a.m. EST / 2:45 p.m. GMT....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
17.11.2025
JAZZ
LISTED
NASDAQ
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom
News Preview
Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim analysis...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
News Preview
– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG –
– Zepzelca® and atezolizumab (Tecentriq®) combination approved as maintenance therapy in 1L ES-SCLC –
– 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex®, Xywav® and the launch o...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
News Preview
– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG –
– Zepzelca® and atezolizumab (Tecentriq®) combination approved as maintenance therapy in 1L ES-SCLC –
– 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex®, Xywav® and the launch o...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
News Preview
Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value
DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Ted W....
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
News Preview
DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. G...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
News Preview
DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. G...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2025
JAZZ
LISTED
NASDAQ
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
News Preview
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial
Zepzelca and atezolizumab combination added to National Comprehensive Cancer Network® Guidelines for SCLC...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
News Preview
20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine
Novel results from the Phase 4 DUET trial underscore the significance of appropriate treatment options in adults with narcolepsy or idiopathic hypersomnia
For U.S. media and investors only
DUBLIN, Sept. 22, 2025 /PRNewswire/ -- Jazz Pharmac...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
09.09.2025
JAZZ
LISTED
NASDAQ
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
News Preview
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United States
For U.S. media and investors only
DUBLIN, Sept. 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
News Preview
DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an overview of clinical data, patient need and commercialization strategy for Modeyso™ (dordaviprone). Modeyso was approved under accelerated approval by the U.S. Fo...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
News Preview
DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an overview of clinical data, patient need and commercialization strategy for Modeyso™ (dordaviprone). Modeyso was approved under accelerated approval by the U.S. Fo...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
News Preview
Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications
For U.S. media and investors only
DUBLIN and COPENHA...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
News Preview
DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter fin...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
News Preview
DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter fin...
Themefolio
Profiler
Peergroup
© PR Newswire
10.07.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
News Preview
– Selection Follows Robust Succession Process Led by the Board –
– Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors –
DUBLIN, July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating...
Themefolio
Profiler
Peergroup
© PR Newswire
10.07.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
News Preview
– Selection Follows Robust Succession Process Led by the Board –
– Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors –
DUBLIN, July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
News Preview
– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial –
DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted conditional marketing authorization1 for Ziihera® (zanidatamab), a dual human epidermal growth factor receptor 2 (HER2)...
Themefolio
Profiler
Peergroup
© PR Newswire
10.06.2025
JAZZ
LISTED
NASDAQ
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
News Preview
Target Action (PDUFA) Date set for October 7, 2025
Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting
Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m....
Themefolio
Profiler
Peergroup
© PR Newswire
10.06.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
News Preview
First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate
Novel intermediate analysis from the DUET trial cohort of patients taking >9 grams evaluated safety and changes in daytime sleepiness in adults with narcolepsy taking Xy...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
News Preview
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization
First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and ove...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
News Preview
Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile
Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology
For U.S. media and investors only
DUBLIN, June 2, 2025 /P...
Themefolio
Profiler
Peergroup
© PR Newswire
29.05.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
News Preview
Nineteen abstracts, including eleven late-breaking abstracts, underscore Jazz's leadership and extensive research in sleep medicine, and ongoing commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia
For U.S. media and investors only
DUBLIN, May 29, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announc...
Themefolio
Profiler
Peergroup
© PR Newswire
21.05.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
News Preview
DUBLIN, May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:
Jefferies Global Healthcare Conference on Thursday, June 5, 2025
Fireside chat at 6:55 a.m. PDT / 9:55 a.m. EDT / 2:55 p.m. ISTGoldman Sachs 46th Annual Global Healthcare Conf...
Themefolio
Profiler
Peergroup
© PR Newswire
21.05.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
News Preview
DUBLIN, May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:
Jefferies Global Healthcare Conference on Thursday, June 5, 2025
Fireside chat at 6:55 a.m. PDT / 9:55 a.m. EDT / 2:55 p.m. ISTGoldman Sachs 46th Annual Global Healthcare Con...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
News Preview
– Total revenues of $898 million in 1Q25 –– Xywav® and Epidiolex® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 –– Completed submission of sNDA for Zepzelca® in 1L ES-SCLC –– Affirming 2025 revenue guidance; updating financial guidance to reflect Chimerix acquisition and impact of certain Xyrem® antitrust litigation settlements –...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
News Preview
DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.
An audio webcast of the fireside cha...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
News Preview
DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.
An audio webcast of the fireside ch...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
News Preview
DUBLIN, April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth fact...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
News Preview
Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients
Long-term outcomes and...
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
News Preview
DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financia...
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
News Preview
DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financia...
Themefolio
Profiler
Peergroup
© PR Newswire
21.04.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Completes Acquisition of Chimerix
News Preview
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need -
DUBLIN, April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chi...
Themefolio
Profiler
Peergroup
© PR Newswire
21.04.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Completes Acquisition of Chimerix
News Preview
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need -
DUBLIN, April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chi...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
News Preview
DUBLIN, March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST.
An audio webcast of the fireside cha...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
News Preview
DUBLIN, March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST.
An audio webcast of the fireside ch...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting
News Preview
Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia by Evaluating Low-Sodium Oxybate Treatment) study
Novel analysis of real-world Epidiolex treatment patterns underscore importance of dose optimizatio...
Themefolio
Profiler
Peergroup
© PR Newswire
05.03.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
News Preview
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-
-Transaction to add near-term commercial opportunity to Jazz's pipeline-
-Transaction represents total cash consideration of approximately $935 million, or $8.55 per share-
DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmace...
Themefolio
Profiler
Peergroup
© PR Newswire
05.03.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
News Preview
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-
-Transaction to add near-term commercial opportunity to Jazz's pipeline-
-Transaction represents total cash consideration of approximately $935 million, or $8.55 per share-
DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmace...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
News Preview
– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
News Preview
– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
News Preview
DUBLIN, Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45th Annual Health Care Conference. Company management will participate in a fireside chat on Wednesday, March 5, 2025, at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.
An audio webcast of the fireside cha...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
News Preview
DUBLIN, Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45th Annual Health Care Conference. Company management will participate in a fireside chat on Wednesday, March 5, 2025, at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.
An audio webcast of the fireside chat...
Themefolio
Profiler
Peergroup
© PR Newswire
11.02.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
News Preview
DUBLIN, Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 fu...
Themefolio
Profiler
Peergroup
© PR Newswire
11.02.2025
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
News Preview
DUBLIN, Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 fu...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025,...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025,...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces CEO Succession Plan
News Preview
Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board
Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue
Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Complete...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces CEO Succession Plan
News Preview
Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board
Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue
Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Complete...
Themefolio
Profiler
Peergroup
© PR Newswire
06.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
News Preview
Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms
Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex®) surveys, which show outcome...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
News Preview
Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States
For U.S. media and investors only
DUBLIN, Dec. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intrav...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
News Preview
DUBLIN, Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. GMT to provide an overview of clinical data, patient need and commercialization strategy for Ziihera® (zanidatamab-hrii), the first chemotherapy-free dual HER2-target...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
News Preview
DUBLIN, Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. GMT to provide an overview of clinical data, patient need and commercialization strategy for Ziihera® (zanidatamab-hrii), the first chemotherapy-free dual HER2-target...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
News Preview
Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment
DUBLIN, Dec. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at th...
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
News Preview
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.
Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial
Company to ho...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
News Preview
DUBLIN, Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024, at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT.
An audio webcast of the fireside chat wi...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2024
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
News Preview
DUBLIN, Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024, at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT.
An audio webcast of the fireside chat wil...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
